HistoRx Inc., a bioscience company offering novel digital technologies for in situ diagnostics developed at the School of Medicine, has located its operations at 25 Science Park in New Haven.
The company has exclusive license to the AQUA (Automated Quantitative Analysis) technology developed by two of the company's founders, Dr. David Rimm and Dr. Robert Camp, both in Yale's Department of Pathology.
AQUA enables researchers to localize and quantify proteins in tissue while maintaining spatial relationships -- a process that was previously impossible with conventional methods of pathology analysis and which vastly increases the quality and amount of information for analysis.
"What is unique about AQUA is that it is completely objective -- it takes subjectivity out of the pathology diagnosis," says Rimm.
HistoRx also holds exclusive license to databases from Yale's tissue archive containing 20- to 40-year clinical follow up information corresponding to different types of human cancer. The School of Medicine's archive holds more than three million tissue samples collected over the past 70 years.
The company provides contract services to academic institutions, pharmaceutical and biotechnology companies while selectively licensing its technologies to leading academic and research laboratories.
Robert Curtis, president, chief executive officer and another co-founder of HistoRx, says, "The company is grounded in the firm belief that the power of AQUA, coupled with the extensive clinical data of the Yale tissue archive, provides an extraordinary new tool for substantial improvement in tissue analysis both for pharmaceutical research and development, and for patient care."
He notes that HistoRx recently entered into feasibility studies with two major pharmaceutical companies and is scheduled to ship its first systems to two preeminent research universities this week.
Rana Gupta, an investment partner at Navigator Technology Ventures, says that HistoRx's technology has the potential to significantly reduce the risk of clinical trial failure and move new drug candidates through the development process more quickly.
According to Jon Soderstrom, managing director of the Office of Cooperative Research at Yale, "HistoRx is a great example of the continuing effort of Yale University to expand the biotechnology industry in the New Haven area."
More information about HistoRx is available at www.historx.com.
T H I SW E E K ' SS T O R I E S
Grant to support research on role of viruses in cancer
Series honors graduation of Yale's first Chinese student 150 years ago
Program marks 35th anniversary of Afro-American Cultural Center
Study: Recreational gambling can be good for seniors' health
Yale launches $1 million United Way drive
Symposium to explore past and future of suburbanization
Event honors late historian of American South
New bioscience company at Science Park offering . . .
Exhibit showcases work of long-ignored landscape artist
Mayhew lauded for his studies of party politics
Congress' only Holocaust survivor to discuss . . .
Noted playwright to speak about his life, Jewish religion
Prize-winning poet Adrienne Rich will read from her work
Older marathon runners are making greater strides . . .
Cultivating a culture of trust was topic of inaugural conference
Dwight Hall interns devote the summer to causes in New Haven
Reimbursements now available through direct deposit
IN MEMORIAM
Study shows benefits of treating hypertension in older people
Yale Books in Brief
Bulletin Home|Visiting on Campus|Calendar of Events|In the News
Bulletin Board|Classified Ads|Search Archives|Deadlines
Bulletin Staff|Public Affairs|News Releases|
E-Mail Us|Yale Home